TSU-007 PATENT

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the Application. Deletions are strikethrough and additions are underlined.

Listing of Claims:

- 1. (Currently amended) A cancer gene therapeutic drug composition comprising a carrier cell for gene therapy in treating cancer including a carrier cell to be infected with an oncolytic virus, so as to make the oncolytic virus act on a tumor cell within a living body, wherein the carrier cell is selected from the group consisting of A549 cell, SW626 cell, and HT-3 cell.
- 2. (Currently amended) The <u>cancer gene therapeutic drug composition comprising a carrier cell for gene therapy in treating cancer according to claim 1, wherein the oncolytic virus to be infected to the carrier cell has a promoter selected from the group consisting of 1A1.3B promoter, midkine promoter, β -HCG promoter, SCCA1 promoter, cox-2 promoter, PSA promoter and a tumor specific promoter according to kind of cancer to be treated.</u>
- 3. (Currently amended) The cancer gene therapeutic drug composition comprising a carrier cell for gene therapy in treating cancer according to claim 1, wherein the virus for immunological treatment and the oncolytic virus are selected from the group consisting of adenovirus, herpes virus, lentivirus, HIV virus, retrovirus, reovirus, vesicular stomatitis virus (VSV) and any other oncolytic virus.
- 4. (Withdrawn Currently amended) The cancer gene therapeutic drug composition comprising a carrier cell for gene therapy in treating cancer according to claim 1, further comprising a virus for immunological treatment to be administered for inducing a CTL reaction within the living body to administration of the carrier cell.

TSU-007 PATENT

5. (Withdrawn - Currently amended) The cancer gene therapeutic drug composition comprising a carrier cell for gene therapy in treating cancer according to claim 1, further comprising atelocollagen.

- 6. (Withdrawn Currently amended) The cancer gene therapeutic drug composition comprising a carrier cell for gene therapy in treating cancer according to claim 1, further comprising a GM-CSF expression vector to be infected to the carrier cell before administration.
- 7. (Withdrawn Currently amended) The cancer gene therapeutic drug composition comprising a carrier cell for gene therapy in treating cancer drug according to claim 1, further comprising an iron preparation and/or a porphyrin compound.
- 8. (Currently amended) The cancer gene therapeutic drug composition comprising a carrier cell for gene therapy in treating cancer according to claim 1, further comprising a tumor cell to be administered for tumor vaccination.
- 9. (Withdrawn Currently amended) A <u>eancer gene therapeutic drug-composition comprising a carrier cell for gene therapy in treating cancer including a carrier cell to be infected with an oncolytic virus, so as to make the oncolytic virus act on a tumor cell within a living body, wherein both A549 cell and 293 cell are together used as the carrier cell.</u>
- 10. (Currently amended) The eancer gene therapeutic drug-composition comprising a carrier cell for gene therapy in treating cancer according to claim 2, wherein the virus for immunological treatment and the oncolytic virus are selected from the group consisting of adenovirus, herpes virus, lentivirus, HIV virus, retrovirus, reovirus, vesicular stomatitis virus (VSV) and any other oncolytic virus.